Next Article in Journal
Current Therapeutic Strategies and Novel Approaches in Osteosarcoma
Previous Article in Journal
99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies
Previous Article in Special Issue
The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
Cancers 2013, 5(2), 569-590; doi:10.3390/cancers5020569
Review

Immunotherapy and Immune Evasion in Prostate Cancer

1,* , 1 and 1,2,3,*
Received: 29 March 2013 / Revised: 16 April 2013 / Accepted: 8 May 2013 / Published: 24 May 2013
(This article belongs to the Special Issue Immune Responses to Human Prostate Cancer)
View Full-Text   |   Download PDF [270 KB, uploaded 24 May 2013]   |   Browse Figure
Abstract: Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subsequent development of castration-resistant and metastatic disease. Since prostate cancer is typically a slowly progressing disease, use of immune-based therapies offers an advantage to target advanced tumors and to induce antitumor immunity. This review will discuss the clinical merits of various vaccines and immunotherapies in castrate resistant prostate cancer and challenges to this evolving field of immune-based therapies.
Keywords: prostate cancer; immunotherapy; vaccine; castrate resistant prostate cancer; bispecific antibody prostate cancer; immunotherapy; vaccine; castrate resistant prostate cancer; bispecific antibody
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Thakur, A.; Vaishampayan, U.; Lum, L.G. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers 2013, 5, 569-590.

AMA Style

Thakur A, Vaishampayan U, Lum LG. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers. 2013; 5(2):569-590.

Chicago/Turabian Style

Thakur, Archana; Vaishampayan, Ulka; Lum, Lawrence G. 2013. "Immunotherapy and Immune Evasion in Prostate Cancer." Cancers 5, no. 2: 569-590.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
{"cc_re__cc_re__cc_by_3_0": ["creator\" content=\"Archana Thakur\">\n            <meta name=\"dc.creator\" content=\"Ulka Vaishampayan\">\n            <meta name=\"dc.creator\" content=\"Lawrence Lum\">\n    \n    <meta name=\"dc.type\" content=\"Review\">\n    <meta name=\"dc.source\" content=\"Cancers 2013, Vol. 5, Pages 569-590\">\n    <meta name=\"dc.date\" content=\"2013-05-24\">\n            <meta name =\"dc.identifier\" content=\"10.3390/cancers5020569\">\n    \n    <meta name=\"dc.publisher\" content=\"Multidisciplinary Digital Publishing Institute\">\n    <meta name=\"dc.rights\" content=\"http://creativecommons.org/licenses/by/3.0/\">\n    <meta name=\"dc.format\" content=\"application/pdf\" >\n    <meta name=\"dc.language\" content=\"en\" >\n\t<meta name=\"dc.description\" content=\"Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subseq", "n>\t\t\t  \t\t<a href=\"/search?q=prostate cancer\">prostate cancer</a>;\t\t\t  \t\t<a href=\"/search?q=immunotherapy\">immunotherapy</a>;\t\t\t  \t\t<a href=\"/search?q=vaccine\">vaccine</a>;\t\t\t  \t\t<a href=\"/search?q=castrate resistant prostate cancer\">castrate resistant prostate cancer</a>;\t\t\t  \t\t<a href=\"/search?q=bispecific antibody\">bispecific antibody</a></span>\n\t\t  </div>\n\t\t\n\n\t\t\n\t\t<div class=\"licenseText\" style=\"padding: 1em; text-align: justify;\">\n\t\t\t\t<em>This is an open access article distributed under the <a href=\"http://creativecommons.org/licenses/by/3.0/\" target=\"_blank\">\n\t\tCreative Commons Attribution License</a> which permits unrestricted use, distribution,\n\t\tand reproduction in any medium, provided the original work is properly cited.</em>\n\t\t\t\t</div>\n\n   </div><div id=\"tabs-1\" class=\"ui-tabs-panel\">\n<div id=\"loaded\" style=\"display:none\">No</div><div id=framed_div style=\"display: none\"></div>\n  </div>\n\n  <div id=\"tabs-2\" class=\"ui-tabs-panel\">\n\t\t\t      <div id=\"article_stats_div\" style=\"text-align: center; display: none; border: solid #CCCCCC 1px\"><div id=\"art"], "copyright__copyright__copyright": ["shampayan, U.; Lum, L.G. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers 2013, 5, 569-590.\n\nAMA Style\n\nThakur A, Vaishampayan U, Lum LG. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers. 2013; 5(2):569-590.\n\nChicago/Turabian Style\n\nThakur, Archana; Vaishampayan, Ulka; Lum, Lawrence G. 2013. \"Immunotherapy and Immune Evasion in Prostate Cancer.\" Cancers 5, no. 2: 569-590.\n\n\nCancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert"]}